Your search for bimekizumab returned 57 results

Ixekizumab 80mg/mL; soln for SC inj; preservative-free.

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.

The BLA is supported by data from the phase 3 BE VIVID, BE READY, and BE SURE studies.

The phase 3 BE OPTIMAL study included 852 adults with active psoriatic arthritis who were biologic disease-modifying antirheumatic drug naïve.

The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.

The BE HEARD I and BE HEARD II studies included more than 1000 adults with moderate to severe hidradenitis suppurativa.

The phase 3 BE COMPLETE study included 400 adults with active psoriatic arthritis who were inadequate responders or intolerant to anti-TNF-α therapy.

Bimekizumab (UCB), an investigational treatment for moderate-to-severe plaque psoriasis, met its two primary end points in a second phase 3 trial.

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.

The ongoing phase 3 BE MOBILE 1 study compared the efficacy and safety of bimekizumab to placebo in adults with active nr-axSpA.